Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML

This study has been completed.
Sponsor:
Collaborators:
Cephalon
ChemGenex Pharmaceuticals
Information provided by (Responsible Party):
Teva Pharmaceutical Industries ( Teva Branded Pharmaceutical Products, R&D Inc. )
ClinicalTrials.gov Identifier:
NCT00462943
First received: April 17, 2007
Last updated: June 27, 2014
Last verified: June 2014

April 17, 2007
June 27, 2014
March 2007
December 2010   (final data collection date for primary outcome measure)
  • Percentage of Participants Achieving an Overall Hematologic Response by Subpopulation and Total Population [ Time Frame: Day 1 up to 6 months ] [ Designated as safety issue: No ]

    Subpopulations reflect chronic myeloid leukemia (CML) phases at the time of enrollment: chronic, accelerated, and blast phase. Primary endpoints as adjudicated by the Data Monitoring Committee were used for the primary analyses.

    Overall hematologic response for chronic phase participants includes confirmed complete hematologic response (CHR). Overall hematologic response for accelerated or blast phase participants includes confirmed complete hematologic response (CHR), no evidence of leukemia (NEL), or return to chronic phase (RCP). Hematologic response must last >= 8 weeks to be considered meaningful.

    Response rates by disease phase were examined relative to an a priori value of 2.5% using a one-sided lower 95% exact binomial confidence limit. If the lower limit from the one-sided lower 95% confidence limit exceeds 2.5%, the observed response rate will have exceeded the minimum threshold required to demonstrate efficacy.

  • Percentage of Participants Achieving a Major Cytogenetic Response by Subpopulation and Total Population [ Time Frame: Day 1 up to 9 months ] [ Designated as safety issue: No ]

    Subpopulations reflect chronic myeloid leukemia (CML) phases at the time of enrollment: chronic, accelerated, and blast phase. Primary endpoints as adjudicated by the Data Monitoring Committee were used for the primary analyses.

    Major cytogenetic response includes complete or partial response. Both confirmed and unconfirmed major cytogenetic response is considered meaningful. Unconfirmed response is based on a single bone marrow cytogenetic evaluation for participants where a confirmatory evaluation is not available.

    Complete response shows 0% Philadelphia chromosome positive (Ph+) cells. A partial response shows >0% - 35% Ph+ cells.

    Response rates by disease phase were examined relative to an a priori value of 2.5% using a one-sided lower 95% exact binomial confidence limit. If the lower limit from the one-sided lower 95% confidence limit exceeds 2.5%, the observed response rate will have exceeded the minimum threshold required to demonstrate efficacy.

  • Number of Participants With Treatment-Emergent Adverse Events (TEAEs) by Subpopulation and Total [ Time Frame: up to 4 years ] [ Designated as safety issue: Yes ]

    TEAE are any untoward events that were newly occurring or worsening from Baseline.

    Treatment related toxicity was considered by the investigator to be unrelated, possibly, probably or unknown related to study drug. Severity was graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0 on the following scale: Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life-threatening, Grade 5 = death. A serious adverse event (SAE) is any untoward medical occurrence that is fatal or life-threatening; results in persistent or significant disability or incapacity; requires or prolongs in-patient hospitalization; is a congenital anomaly/birth defect in the offspring of a patient; and conditions not included in the above that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above.

    A participant is only counted once in each category (at worst severity or strongest relationship).

Clinical Response
Complete list of historical versions of study NCT00462943 on ClinicalTrials.gov Archive Site
  • Percentage of Participants in Each Cytogenetic Response Category Representing the Degree of Suppression of the Philadelphia Chromosome (Ph+) [ Time Frame: Day 1 up to Month 9 ] [ Designated as safety issue: No ]

    Cytogenetic response categories:

    • Complete: 0% Ph+ cells
    • Partial: >0%-35% Ph+ cells
    • Minor: >35%-65% Ph+ cells
    • Minimal: >65%-95% Ph+ cells
    • No Response: >95% Ph+ cells
    • Unevaluable: <20 metaphases were examined and/or response could not be assigned
  • Percentage of Participants With Major Molecular Response (MMR) Representing the Degree of Suppression of BCR-ABL Transcript Levels Using the Housekeeping Gene GUS [ Time Frame: Day 1 up to Month 6 ] [ Designated as safety issue: No ]
    MMR is defined as a ratio of BCR-ABL/standard gene of less than 0.1% according to the international scale. BCR-ABL is a fusion gene of the breakpoint cluster region [BCR] gene and Abelson proto-oncogene [ABL] genes). This analysis used the standard gene GUS. Analysis was performed by quantitative reverse transcription polymerase chain reaction (qRT-PCR) of peripheral blood.
  • Percentage of Participants With Major Molecular Response (MMR) Representing the Degree of Suppression of BCR-ABL Transcript Levels Using the Housekeeping Gene ABL [ Time Frame: Day 1 up to Month 6 ] [ Designated as safety issue: No ]
    MMR is defined as a ratio of BCR-ABL/standard gene of less than 0.1% according to the international scale. BCR-ABL is a fusion gene of the breakpoint cluster region [BCR] gene and Abelson proto-oncogene [ABL] genes). This analysis used the standard gene ABL. Analysis was performed by quantitative reverse transcription polymerase chain reaction (qRT-PCR) of peripheral blood.
  • Percentage of Participants in Each Hematologic Response Category [ Time Frame: Day 1 up to Month 6 ] [ Designated as safety issue: No ]

    Complete Response (CHR)

    • Chronic phase must last at least 8 weeks: WBC <10*10^9/liter, platelets <450*10^9/liter, myelocytes + metamyelocytes <5% in blood, no blasts or promyelocytes in blood, <20% basophils in peripheral blood, no extramedullary involvement.
    • Accelerated and Blast phase must last at least 4 weeks: absolute neutrophil count 1.5*10^9/liter, platelets 100*10^9/liter, no blood blasts, bone marrow blasts <5%, no extramedullary disease.

    Partial Response - CHR plus one or more of the following:

    • Persistence of splenomegaly with a reduction of ≥50% from pre-treatment
    • Platelets > 450*10^9/L
    • Presence of immature cells in the peripheral blood
    • 5% to 25% blasts in the bone marrow
    • If extra-medullary disease pre-treatment, reduction by ≥50% Hematologic Improvement - CHR, except allowing persistent thrombocytopenia (<100*10^9/L), and a few immature cells No evidence of leukemia: Morphologic leukemia-free state, defined as <5% bone marrow blasts.
  • Percentage of Participants With Extramedullary Disease (EMD) at Baseline Achieving a Clinical Response [ Time Frame: Day 1 up to Month 9 ] [ Designated as safety issue: No ]

    Clinical response was defined by disease phase and based on evaluations by the independent Data Monitoring Committee (DMC).

    Chronic Phase subgroup: achieving a complete hematologic response and/or major cytogenetic response (complete cytogenetic response or partial cytogenetic response, confirmed or unconfirmed).

    Accelerated Phase and Blast Phase subgroups: achieving complete hematologic response, no evidence of leukemia, return to chronic phase, and/or major cytogenetic response (complete cytogenetic response or partial cytogenetic response, confirmed or unconfirmed).

  • Percentage of Participants With the Largest Percentage Reduction From Baseline of T315I Mutated BCR-ABL [ Time Frame: Day 1 up to Month 9 ] [ Designated as safety issue: No ]
    Summarization is based on the best of the individual response assessments. Not assessable indicates that the participant either had no baseline assessment or the % mutation could not be determined in the post-baseline assessment(s).
  • Number of Treatment Cycles Needed to Achieve Best Hematologic Response [ Time Frame: Day 1 up to Month 6 ] [ Designated as safety issue: No ]
    Induction therapy was administered for 14 consecutive days for each 28 days cycle, for up to 6 cycles. All treatment arms were given omacetaxine mepesuccinate via subcutaneous (SC) administration at 1.25 mg/m^2 twice a day (BID) for the 14 consecutive days.
  • Number of Treatment Cycles Needed to Achieve Best Cytogenetic Response [ Time Frame: Day 1 up to Month 9 ] [ Designated as safety issue: No ]
  • Kaplan-Meier Estimates for Time to Onset of Best Hematologic Response [ Time Frame: Day 1 up to Month 6 ] [ Designated as safety issue: No ]

    Time to onset was analyzed using Kaplan-Meier estimates. Participants who did not achieve a response are censored at their last visit day.

    Overall hematologic response for chronic phase participants includes confirmed complete hematologic response (CHR). Overall hematologic response for accelerated or blast phase participants includes confirmed complete hematologic response (CHR), no evidence of leukemia (NEL), or return to chronic phase (RCP). Hematologic response must last >= 8 weeks to be considered meaningful.

  • Kaplan-Meier Estimates for Time to Onset of Best Cytogenetic Response [ Time Frame: Day 1 up to Month 9 ] [ Designated as safety issue: No ]

    Time to onset was analyzed using Kaplan-Meier estimates. Participants who did not achieve a response are censored at their last visit day.

    Major cytogenetic response includes complete or partial response. Both confirmed and unconfirmed major cytogenetic response is considered meaningful. Unconfirmed response is based on a single bone marrow cytogenetic evaluation for participants where a confirmatory evaluation is not available.

    Complete response shows 0% Philadelphia chromosome positive (Ph+) cells. A partial response shows >0% - 35% Ph+ cells.

  • Kaplan-Meier Estimates for Duration of Best Hematologic Response [ Time Frame: up to four years ] [ Designated as safety issue: No ]
    Duration of response is defined as the time from first reported date of hematologic response until the earliest date of objective evidence of disease progression, relapse or death. Data was censored at the last examination date for participants with ongoing response or participants who discontinued treatment for reasons other than adverse event, disease progression or death.
  • Kaplan-Meier Estimates for Duration of Best Cytogenetic Response [ Time Frame: up to four years ] [ Designated as safety issue: No ]
    Duration of response is defined as the time from first reported date of cytogenetic response until the earliest date of objective evidence of disease progression, relapse or death. Data was censored at the last examination date for participants with ongoing response or participants who discontinued treatment for reasons other than adverse event, disease progression or death.
  • Kaplan-Meier Estimates for Time to Disease Progression [ Time Frame: up to 4 years ] [ Designated as safety issue: No ]
    Time to disease progression is defined as the time from the initiation of treatment until the onset date of death, the development of CML accelerated phase or blast phase, or the loss of complete hematologic response or major cytogenetic response, whichever came first. Participants were censored only if they did not have progression or if they discontinued treatment for reasons other than AE, progression or death.
  • Kaplan-Meier Estimates for Overall Survival [ Time Frame: up to 4 years ] [ Designated as safety issue: No ]
    Overall survival is defined as the time from the initiation of treatment until death from any cause or the last day of participant contact or evaluation for participants that were lost to follow-up. Participants were censored t the last recorded contract or evaluation when a participant was alive at time of analysis. A quarterly phone survey was conducted to collect survival data for participants who discontinued from the study.
  • Degree of Hematologic Response
  • Time to Response
  • Time to progression
  • Survival
Not Provided
Not Provided
 
Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML
A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine (Omacetaxine Mepesuccinate) in the Treatment of Patients With Chronic Myeloid Leukemia (CML) Who Have Failed or Are Intolerant to Tyrosine Kinase Inhibitor Therapy

A Phase II open-label trial of subcutaneous HHT (omacetaxine mepesuccinate) in the treatment of patients who are resistant to or intolerant to Tyrosine Kinase Inhibitors.

This will be an open label, multicenter study of subcutaneous HHT (omacetaxine mepesuccinate) therapy of patients with chronic myeloid leukemia (CML) in chronic, accelerated, or blast phase who have failed or are intolerant to tyrosine kinase inhibitor therapy. Patients will be treated with induction course cycles consisting of subcutaneous (SC) HHT 1.25 mg/m² twice daily for 14 consecutive days every 28 days. Patients will be evaluated every 7 days with complete blood and platelet counts while undergoing induction therapy; the number of consecutive doses of HHT or intervals between subsequent cycles may be adjusted, as clinically indicated, according to guidelines provided in the treatment plan.

Interventional
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Chronic Myeloid Leukemia
Drug: Omacetaxine mepesuccinate

Induction: 1.25mg/m^2 subcutaneously twice daily for 14 consecutive days, every 28 days.

Maintenance: 1.25mg/m^2 subcutaneously twice daily for 7 consecutive days, every 28 days.

Response targets during induction vary by chronic myeloid leukemia (CML) subclass (chronic, accelerated, or blast phase). Participants will complete at least one cycle (14 days treatment of a 28 day cycle) of induction therapy before changing to maintenance therapy. Participants not demonstrating evidence of clinical response after 6 induction cycles will be considered for removal from the study.

Other Names:
  • Homoharringtonine
  • HHT
  • Synribo
  • OMA
  • CGX-635
Experimental: OMA

Omacetaxine mepesuccinate (OMA) Induction: 1.25mg/m^2 subcutaneously twice daily for 14 consecutive days, every 28 days for up to six cycles.

Omacetaxine mepesuccinate (OMA) Maintenance: 1.25mg/m^2 subcutaneously twice daily for 7 consecutive days, every 28 days for up to 24 months.

Intervention: Drug: Omacetaxine mepesuccinate
Cortes J, Digumarti R, Parikh PM, Wetzler M, Lipton JH, Hochhaus A, Craig AR, Benichou AC, Nicolini FE, Kantarjian HM; Omacetaxine 203 Study Group. Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors. Am J Hematol. 2013 May;88(5):350-4. doi: 10.1002/ajh.23408. Epub 2013 Mar 7.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
100
September 2013
December 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female patients, age 18 years or older
  • Philadelphia chromosome (Ph) positive chronic myelogenous leukemia in either chronic, accelerated, or blast phase
  • Patients will have either failed, demonstrated intolerance, or a combination of prior failure and intolerance, to prior treatments with at least two tyrosine kinase inhibitors (TKI's). Failure of TKI treatment may either be primary (never achieved a response) or secondary resistance (loss of response).
  • Acceptable Renal and Liver Function
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
  • Sexually active patients and their partners must use an effective double barrier method of contraception

Exclusion Criteria:

  • New York Heart Association classification (NYHA) class III or IV heart disease, active ischemia or any other uncontrolled cardiac condition
  • Myocardial infarction in the previous 12 weeks.
  • Other concurrent illness which would preclude study conduct and assessment
  • uncontrolled and active infection, and positive HIV or positive HTLV I/II status, whether on treatment or not.
  • Pregnant or lactating.
  • Any medical or psychiatric condition, which may compromise the ability to give written informed consent or to comply with the study protocol.
  • Lymphoid Ph+ blast crisis
  • Patient is enrolled in another clinical investigation within 30 days of enrollment or is receiving another investigational agent
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States,   Canada,   France,   Germany,   Hungary,   India,   Italy,   Poland,   Singapore,   United Kingdom
 
NCT00462943
CGX-635-CML-203, 2007-001286-15
Yes
Teva Pharmaceutical Industries ( Teva Branded Pharmaceutical Products, R&D Inc. )
Teva Branded Pharmaceutical Products, R&D Inc.
  • Cephalon
  • ChemGenex Pharmaceuticals
Principal Investigator: Jorge Cortes, MD M.D. Anderson Cancer Center
Teva Pharmaceutical Industries
June 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP